Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2024 Oct 15.
Published in final edited form as: J Immunol. 2023 Oct 15;211(8):1195–1201. doi: 10.4049/jimmunol.2300378

Infection dynamics, pathogenesis and immunity to SARS-CoV-2 in naturally susceptible animal species

Mohammed Nooruzzaman , Diego G Diel †,*
PMCID: PMC10558081  NIHMSID: NIHMS1919744  PMID: 37782853

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causative agent of the coronavirus disease 2019 (COVID-19) pandemic, presents a broad host range. Domestic cats and white-tailed deer (WTD) are particularly susceptible to SARS-CoV-2 with multiple variant strains being associated with infections in these species. The virus replicates in the URT and in associated lymphoid tissues, and is shed through oral and nasal secretions, which leads to efficient transmission of the virus to contact animals. Robust cell mediated and humoral immune responses are induced upon infection in domestic cats which curb the progression of clinical disease and are associated with control of infection. In WTD, high levels of neutralizing antibodies are detected early upon infection. In this review, the current understanding of the infection dynamics, pathogenesis, and immune responses to SARS-CoV-2 infection in animals, with special focus on naturally susceptible felids and WTD are discussed.

Keywords: SARS-CoV-2, cats, white-tailed-deer, infection dynamics, immune response

Introduction

Coronaviruses are a diverse group of viruses that infect different animal species and have long been recognized for their pandemic potential. Two highly pathogenic coronaviruses of zoonotic origin, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome CoV (MERS-CoV) causing fatal respiratory illness in humans emerged in 2002 and 2012, respectively, making coronaviruses a major public health threat (1). The most recent and notable CoV threat that emerged in human is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – causative agent of the coronavirus disease 2019 (COVID-19) pandemic, which was first detected in humans in Wuhan, China in December 2019 (2). Like SARS and MERS, COVID-19 patients also showed symptoms of viral pneumonia, including fever, cough, and chest discomfort, and in severe cases dyspnea and bilateral lung infiltration and death (2).

All previously described human coronaviruses (human coronavirus HKU1 [HCoV-HKU1], HCoV-229E, HCoV-NL63, HCoV-OC43, MERS-CoV and SARS-CoV) have zoonotic origins resulting from spillover events associated with intermediate animal hosts (3). Epidemiological studies suggest that the Huanan market in Wuhan city was a major epicenter of SARS-CoV-2 infection as 27 (66%) of the first 41 human cases of COVID-19 were linked to the market (4), which reportedly sold seafood and live animals for human consumption, including poultry, bats, marmots, cervids, raccoon dogs, and several other wild species (5). Viruses closely related to SARS-CoV-2 have been detected in bats and pangolins in multiple localities in South-East Asia, including in China, Thailand, Cambodia, and Japan (6, 7). A bat virus, named RaTG13, detected in Rhinolophus affinis in Yunnan, China presenting 96.2% nucleotide similarity at whole genome level with SARS-CoV-2 represents the closest relative to SARS-CoV-2 identified to date (6, 8). Other bat viruses such as RmYN02 from Rhinolophus malayanus bat sampled in Yunnan, China (9), bat coronaviruses ZC45 and ZXC21 previously detected in Rhinolophus pusillus bats in eastern China (10) also cluster with the SARS-CoV-2 lineage of the subgenus Sarbecovirus, suggesting that bats could be a reservoir for SARS-CoV-2-like viruses. Recent evidence suggests that raccoon dogs present at the Huanan market at the time the pandemic started may have been exposed to SARS-CoV-2 (11), however, whether this or any other animal species commercialized in the market served as an intermediate host before the virus jumped into humans, remains unknown.

SARS-CoV-2 is a single-stranded, positive-sense RNA virus, belonging to the Coronaviridae family, Orthocoronavirinae subfamily, Betacoronavirus genus and Sarbecovirus subgenus. The virus genome is ~30 kb in length, and it shares ~80% sequence homology with SARS-CoV. The genome contains 14 open reading frames (ORFs) which encode 29 viral proteins. About two thirds of the viral genome encode two overlapping polyproteins (pp): pp1a and pp1ab (12). These polyproteins are cleaved by two viral proteases (NSP3 and NSP5) into 16 non-structural proteins, which are essential for viral replication and transcription. The 3′ end of the genome encodes ORFs for four structural proteins, including the spike (S), envelope (E), membrane (M), and nucleocapsid (N) protein which participate in virion assembly, entry and/or suppress host immune responses. Several accessory proteins such as ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8, ORF9b, ORF9c and ORF10 are encoded at the 3ʹ end of the genome as individual ORFs and contribute to viral pathogenesis and host immune evasion (13, 14).

The S protein functions in viral entry and mediates receptor binding and fusion. Receptor binding and membrane fusion are key steps for coronaviruses to achieve cross-species infection and establish efficient transmission pathways in new host species. The SARS-CoV-2 S protein is one of the main determinants of cellular susceptibility as it mediates virus entry and cell fusion, through its direct interaction(s) with the cellular receptor (angiotensin-converting enzyme 2 [ACE2]) – and host cellular proteases (furin and transmembrane serine protease 2 [TMPRSS2])(15). Thus, at the cellular level susceptibility to SARS-CoV-2 is dependent minimally on the expression of a compatible cellular ACE2 receptor that allows efficient binding of the virus S protein and triggers subsequent cleavage of S1/S2 and S2ʹ sites by ubiquitous furin-like proteases and TMPRSS2, respectively, enabling fusion of the virus envelope and host cell membranes.

At the host level, SARS-CoV-2 susceptibility is also affected by efficient ACE2 receptor recognition. However, receptor binding is only the first step in virus infection. Host factors that enable virus replication in the cytoplasm making cells permissive to infection also play a critical role. Additionally, the expression levels of key entry factors (ACE2 and TMPRSS2) in susceptible/permissive cells and the localization and accessibility of these cells in target tissues is crucial for virus infection. Finally, the ability of the virus to bypass intrinsic host restriction factors elicited to control the infection locally in target cells and tissues (16) or systemically are also very important determinants of susceptibility and host range to SARS-CoV-2.

Natural SARS-CoV-2 infections in animals

Natural SARS-CoV-2 infection have been reported in many species, including minks, ferrets, lions, tigers, cats, and white-tailed deer (WTD) (17). As of April 26, 2023, a total of 754 cases of SARS-CoV-2 infection have been recorded globally involving 32 animal species from 39 countries (18), with most SARS-CoV-2 variants being detected in animals. While most animal infections are subclinical, case fatality rates approaching ~35–55% have been reported in mink (19).

Cats are highly susceptible to SARS-CoV-2 infection (17, 2022). Most SARS-CoV-2 infections in cats involve natural human-to-cat transmission of the virus (2332). Several variants including Alpha (B1.1.7), Delta (AY.3), and Omicron (B1.1.529) have been detected in cats (20, 29, 3336). Experimental SARS-CoV-2 infections in cats confirmed efficient virus replication in the respiratory tract, prolonged virus shedding in respiratory and oral secretions and development of lesions characteristic of SARS-CoV-2 infection in humans (22, 3740). Additionally, the potential for cat-to-cat transmission of SARS-CoV-2 has been demonstrated (3739, 41, 42).

Natural SARS-CoV-2 infections have also been reported in other felids including tigers and lions, which like infections in domestic cats have been linked to human-to-animal transmission events (18, 4348). Affected animals may present subclinical infections or present with lethargy, anorexia, and mild respiratory signs (4548). The first reported infected Malayan tiger presented necrosis in the trachea with viral RNA being detected in necrotic cells in tracheal wash fluid by in situ hybridization (ISH) (48). Other felids such as cougars and snow leopards are also naturally susceptible to SARS-CoV-2 infection (18, 43).

The susceptibility of minks to SARS-CoV-2 was first reported during an outbreak affecting farmed mink in April 2020 in the Netherlands (49). The affected minks presented mild to severe respiratory distress with several animals dying of interstitial pneumonia. Importantly, during this outbreak mink-to-mink transmission was documented (49). After the initial outbreak in the Netherlands, several outbreaks were reported in mink farms globally including in Denmark (50), Poland (51), Spain (52), and United States (53). Notably, infection and transmission of SARS-CoV-2 in mink resulted in adaptive mutations in the virus genome, and viruses with these mink-origin mutations were detected in humans, suggesting mink-to-human transmission of the virus (54, 55). These findings raised concerns about the potential establishment of a new reservoir of SARS-CoV-2 in mink.

One of the most remarkable findings regarding SARS-CoV-2 host range, was the fact that white-tailed-deer (WTD) (Odocoileus virginianus) were shown to be highly susceptible and capable of transmitting SARS-CoV-2 to non-infected contact animals (5658). Most importantly, multiple infections in free-ranging WTD have been reported in the United States and Canada. Genomic surveillance and sequence analysis of SARS-CoV-2 strains recovered from WTD indicate efficient deer-to-deer transmission of the virus (5961), with recent evidence suggesting rare, but possible spillback to humans (62).

SARS-CoV-2 pathogenesis and immune responses in cats

Although most of the natural outbreaks and experimental infection of SARS-CoV-2 are subclinical in cats, productive virus replication and pathology are observed mainly in the respiratory tract of affected animals. Infected cats transmit the virus to contact animals and both primary and contact infected cats seroconvert and resist reinfection with the virus. The infection dynamics and immune responses to SARS-CoV-2 infection in cats are reviewed here based on several experimental studies and summarized in Figure 1 (21, 22, 37, 4042, 63, 64).

FIGURE 1.

FIGURE 1.

Infection dynamics and immune responses in cats following experimental SARS-CoV-2 infection. SARS-CoV-2 infected cats develop mild clinical signs characterized by elevated body temperature between 1–3 days post-infection (dpi). The virus replicates in the respiratory tract and nearby lymphoid tissues and is shed through nasal and oral secretions mostly during the first week of infection. Rhinitis and tracheobronchitis, bronchiolitis and interstitial pneumonia have been consistently detected during the first week of infection while chronic lesions in the lungs have also been reported. Significant shift in systemic lymphocyte immunophenotype with increases frequency of CD4+ T cell response and decreases in the frequency of CD21+ B cells have been reported during 2–8 dpi. Eventually, infected animals produce neutralizing antibodies (NA) which are detected as early as 7 dpi and both IgG and IgM antibodies have been detected against RBD of Spike and N protein.

Clinical outcome of SARS-CoV-2 infection in cats

The clinical outcome of SARS-CoV-2 infection in domestic cats has been variable, depending on the virus strain, dose and route of inoculation, and age of the animals. Most experimental studies using the ancestral SARS-CoV-2 strains and natural routes of infection (intranasal and/or oral) have reported subclinical infection without notable changes in body temperature or body weight (21, 37, 39, 41, 42). No significant changes in hematological and serum biochemical parameters have been reported (37). In contrast, intratracheal inoculation of SARS-CoV-2 in cats has been shown to result in marked clinical disease with animals presenting lethargy, increased respiratory effort, fever and weight loss (64). A comparative pathogenicity study with SARS-CoV-2 variants shows elevated body temperature, loss of body weight, lethargy, and respiratory signs for 1–3 days post-infection (dpi) in cats infected with the ancestral B.1 D614G and Delta (B.1.617.2) variants and subclinical infection in omicron BA1.1-infected cats (22).

Infection dynamics of SARS-CoV-2 in cats

Following replication of SARS-CoV-2 in the respiratory tract, viral RNA and infectious virus have been consistently detected in respiratory tissues (nasal turbinate, trachea, and lungs) and associated lymphoid organs including tonsil and retropharyngeal lymph nodes between 3 and 5 dpi (21, 22, 37, 4042), with the highest viral loads detected at 3–4 dpi (21, 22, 37). Viral RNA is detected in the lungs between days 3–14 dpi with infectious virus being recovered between days 3–5 pi. Infected animals usually clear the infection from both upper and lower respiratory tissues by 10 dpi (22, 40). Limited viral RNA, but no infectious virus has been detected in the upper respiratory tract (URT) and lymphoid organs up to 21 dpi (37, 42). Viral RNA has been detected in the bronchoalveolar lavage fluid between 3–14 dpi with the highest viral loads detected at 3–5 dpi (22, 37, 42), however, infectious virus has only been detected between 3 and 5 dpi (22).

In addition to the respiratory tract, viral RNA has been detected in the heart, mediastinal lymph node, liver, spleen, kidney, small intestine, and mesenteric lymph node at 3–21 dpi (21, 22, 37, 41, 42). However, infectious virus was not detected in non-respiratory tissues (21, 22, 40, 41). Interestingly, viral RNA or infectious virus is usually not detected in the blood or serum of infected cats (37), which suggest alternative route(s) of virus dissemination from the initial sites of virus replication in the respiratory tract to other organs and systems.

Infected cats shed SARS-CoV-2 in nasal, and oral secretions with low levels of viral RNA also being transiently detected in feces. Viral RNA is detected in nasal secretions between 1 and 14 dpi, with peak viral RNA loads observed at 3 to 5 dpi (22, 37, 42). Importantly, high level infectious virus shedding in nasal secretions is detected up to 7 dpi with sporadic detection at 10 and 14 dpi (22, 41). A similar kinetics of virus shedding is also observed in oral secretions, however, the virus titers recovered are approximately one log lower than those recovered from nasal secretions (22, 37, 41, 42). Shedding of viral RNA in feces is markedly lower than in respiratory and oral secretions (22, 37, 42).

Differences in the infection and virus shedding dynamics have been observed in cats inoculated with different SARS-CoV-2 variants (22). A study comparing the pathogenicity of three SARS-CoV-2 variants (the ancestral B.1 D614G, Delta [B1. 617.2] and Omicron [BA1.1]) reported significant lower virus shedding in nasal, oral secretions, and feces in Omicron-inoculated cats than in cats inoculated with B.1 D614G and Delta viruses (22). Similarly, lower virus titers were detected in tissues of Omicron-inoculated cats than in B.1 D614G- and Delta-inoculated cats. While D614G and Delta-viruses present broad tissue tropism and abundant replication in nasal turbinate, palate/tonsil, trachea, retropharyngeal lymph node and lungs at 3 and 5 dpi, the Omicron replication was mainly confined to the URT (nasal turbinate and trachea) with much lower viral loads detected in lungs (22).

Consistent with robust SARS-CoV-2 replication in the URT and shedding in respiratory secretions, the virus is efficiently transmitted between infected and contact cats (37, 41, 42). Current studies demonstrate efficient transmission from infected to contact animals as early as 1–2 days post-contact (37). Contact cats shed infectious virus through oral and nasal secretions by 1–2 days post-contact with peak shedding occurring at day 7 post-contact (37).

Pathological changes following SARS-CoV-2 infection in cats

SARS-CoV-2 infection in cats produces pulmonary lesions that resemble lesions observed in humans with acute respiratory distress syndrome from COVID-19 (64).

Upon intranasal inoculation, the lungs of cats infected with the SARS-CoV-2 strain USA-WA1/2020 present various degrees of edema, discoloration, congestion, and atelectasis (37). Notably, intratracheal inoculation of cats with SARS-CoV-2 strain WA1/2020 results in more severe outcome and inoculated animals present marked pathology in lungs characterized by large multifocal to coalescing regions of dark red consolidation with edema at 4 dpi which become more pronounced at 8 dpi (64). Similarly, intratracheal inoculation of cats with the Delta variant results in severe consolidation, hemorrhages, and edema in lungs (63).

Histological changes are usually limited to URT and bronchial tree in lungs of infected cats. In the nasal passage, ulcerative neutrophilic rhinitis is accompanied by neutrophil infiltration of the lamina propria and accumulation of fibrin aggregates, cellular debris, degenerated epithelial cells and leukocytes (22, 41, 42). Epithelial cells of the nasal mucosa are the main target of SARS-CoV-2 replication, with extensive viral RNA labeling observed by ISH at 3–5 dpi (22). SARS-CoV-2 NP antigen and viral RNA are also detected within squamous (in rostral turbinate) and respiratory epithelial cells (in intermediate and deep turbinate) (42). Lesions in the trachea are characterized by epithelial degeneration, necrosis and regeneration associated with a mixed inflammatory infiltrate (22). Multifocal lymphocytic and neutrophilic tracheobronchoadenitis of seromucous glands of the laminar propria and submucosa of the trachea and bronchi have been reported at 4 dpi, which progress to mild to moderate at 7 dpi (37). Viral staining is detected in cells within submucosal interstitial stroma and submucosal glands (22, 37, 42). Affected submucosal glands and associated ducts are variably distended, lined by attenuated epithelium, and contain necrotic cell debris and infiltrating lymphocytes, macrophages, and plasma cells (37).

In lungs, mild bronchitis with lymphoid hyperplasia, moderate to severe histiocytic bronchiolitis with partial to complete occlusion of lumina, moderate to severe thickening of alveolar septa are reported at 3 dpi (22, 40). The interstitial inflammation seems to resolve quickly, while alveolar septal thickening persists up to 10 dpi (40). The bronchus-associated lymphoid tissue becomes hyperplastic containing a mixture of CD3+ and CD20+ lymphocytes (65). Persistent lung lesions are observed as late as 28 dpi and include histiocytic bronchiolitis with luminal plugs and thickened alveolar septa coupled with perivascular fibrosis and vascular proliferation within the thickened interstitium (40). The specific cell types that contribute to the interstitial thickening include CD3+ T lymphocytes, CD20+ B lymphocytes, CD204+ macrophages, and fewer plasma cells (65). The perivascular lymphoid aggregates are also MHC II positive. Additionally, abundant type II pneumocytes are scattered within the alveolar septa. The bronchiolar plugs consist of round to epithelioid cells with foamy to slightly fibrillar eosinophilic cytoplasm consistent with viable and degenerative Iba-1+ and CD204+ macrophages (65). At later time points (28 dpi), increased numbers of bronchioles show variable remodeling with occasional erosion, robust epithelial proliferation, and segmental bronchiolar constriction (65). Hypertrophy of smooth muscle of terminal bronchioles and bronchioles are also noticed at 28 dpi (65). Staining of viral RNA in the lung is more frequent in the interstitial regions especially in cells of the bronchiolar glands at early time points (3–5 dpi) (22). No viral RNA or antigen are detected within lining epithelial cells or elsewhere in the pulmonary parenchyma, including smaller airways and alveoli (22, 37). A comparative pathogenicity of three SARS-CoV-2 variants, B.1 D614G, Delta (B1.617.2) and Omicron (BA1.1) revealed contrasting pathology in respiratory tissues (22). The degree and duration of pathological changes observed in the respiratory tract were higher in B.1 D614G and Delta-infected cats than the Omicron. Striking differences are noticed in the lungs across variants, with the B.1 D614G and Delta infected cats showing marked bronchial and bronchiolar necrosis, degeneration, and mixed inflammation in lungs, while no necrotizing lesions are observed in Omicron infected cats (22).

No lesions are identified in extrapulmonary tissues of SARS-CoV-2 infected cats other than mild lymphoid hyperplasia (42). While other study reports no histologic lesions or viral staining in the palate/tonsil, retropharyngeal lymph node and heart of SARS-CoV-2 infected cats (22).

Immune responses to SARS-CoV-2 in cats

Studies addressing the immune responses of SARS-CoV-2 in cats are limited. Expression of innate immune cytokines, divergent lymphocyte phenotypes, and neutralizing antibody responses during SARS-CoV-2 infection in cats are summarized below.

High level of proinflammatory cytokines such as IL-2, GM-CSF, CXCL1 (neutrophil chemoattractant) at 3 dpi and IL-1β, TNF-α, IL-2, IL-4, IL-6, and CXCL1 at 7 dpi, were observed in B.1 D614G- and Delta variant-inoculated cats when compared to Omicron-inoculated animals. In contrast, increased level of anti-inflammatory cytokines IFN-γ and CCL5 were observed in Omicron-inoculated cats which mirrored the lower pathogenicity of this variant in cats (22). However, more detailed functional studies, particularly their expression in the highly susceptible upper and lower respiratory tract of cats are needed to elucidate the role and contribution of innate immune cytokines in the pathogenicity of SARS-CoV-2 in this species.

A recent study reports significant shift in systemic lymphocyte immunophenotypes during SARS-CoV-2 Delta variant infection in cats (63). A steady increase in the proportion of CD4+ T cells through 8 dpi was observed in infected cats suggesting a T cell-mediated proinflammatory (Th1) response that may contribute to immunopathology (63). While CD8+ T cells that are essential for virus clearance during acute infection, remained unaltered throughout the course of infection (63), the proportion of CD21+ B cells was reduced in infected cats throughout the study period, resembling observations in untreated human COVID-19 patients, possibly due to B-cell exhaustion and exacerbated immune activation (63, 66). Further studies are required to elucidate the protective mechanisms of CD8+ T cells and the contribution of these and other lymphocyte subtypes in the control of infection and viral clearance from tissues in domestic cats.

Robust neutralizing antibody responses are developed by SARS-CoV-2 infected cats (42). Virus neutralizing antibodies are detected in serum as early as 7 dpi (22, 37, 41) and remain elevated for up to 28 to 42 dpi (41). Antibodies against NP and S RBD are detected as early as 5 dpi in infected cats by ELISA (37). Serum IgG antibody responses against full-length S and the RBD as well as NP are detected at 7 dpi, which increase at 14 and 21 dpi (41). Seroconversion to the S protein seems to be fast and robust, and the specificity of response to RBD exceeds that of NP (41). Serum IgM antibodies against RBD are detected at 7 and 14 dpi but not at 28 dpi and the IgM responses are less robust than the IgG (41).

Of note, cross-neutralization assays revealed cross-neutralizing antibody activity in serum from B.1 D614G-inoculated cats against the Delta but not against the Omicron variant. Interestingly, sera from Delta-inoculated cats presented neutralizing activity to both the B.1 D614G and Omicron variants. Animals infected with the Omicron variant, however, presented lower and delayed neutralizing antibody responses (35).

SARS-CoV-2 pathogenesis and immune responses in white-tailed deer

White-tailed deer (WTD) are one of the most abundant large ruminant species in North America. The ACE2 protein of WTD shares high amino acid homology with that of human ACE2, thus allowing efficient binding of SARS-CoV-2 S protein and entry into cells (67). Such ACE2 homology makes WTD highly susceptible to diverse SARS-CoV-2 lineages of human origin (61). Detailed experimental studies in WTD, revealed some of the basic aspects of the virus infection dynamics and pathogenesis in this species (5658). A summary of SARS-CoV-2 infection dynamics in WTD is presented in Figure 2 and discussed in further detail in the sections that follow.

FIGURE 2.

FIGURE 2.

Infection dynamics and immune responses of SARS-CoV-2 infection in WTD. SARS-CoV-2 infected WTD show a slight elevation in body temperature at 1–3 dpi. Infectious viruses in the nasal and oral secretions have been detected during the first week of infection. Infected WTD transmit the virus to contact animals by 3 dpi. Pathology such as rhinitis, tracheobronchitis, bronchiolitis and tonsilitis have been observed during acute stage of infection (2–5 dpi). Neutralizing antibodies (NA) are detected in both primary infected and contact animals as early as 7 dpi.

Infection dynamics of SARS-CoV-2 in WTD

Infection of WTD with SARS-CoV-2 are usually subclinical (5658). However, a slight and transient increase in the body temperature has been observed between 1–3 dpi in infected fawn and adult deer (5658).

SARS-CoV-2 productively infects and replicates in the URT and associated lymphoid organs in WTD. During the acute stage of infection (2–5 dpi), infectious virus is consistently detected in a broad range of tissues including nasal turbinate, tonsil (palatine and pharyngeal), lymph nodes (medial retropharyngeal, mandibular, and tracheobronchial) and in the trachea, bronchus, and lungs (58). Of note, infectious virus has also been detected in olfactory lobe, caudate nucleus of brain, cerebrum, and cerebellum at 2 dpi in infected WTD (57). However, no infectious virus has been detected in any tissues after 5 dpi (56).

Virus shedding has been detected in nasal and oral secretions and less consistently in feces of infected WTD (5658). In an experimental infection in fawns with the SARS-CoV-2 ancestral B.1 lineage shedding of viral RNA has been detected in the nasal and oral secretions between 2 to 21–22 dpi, with higher viral RNA loads detected between 2 and 7 dpi and decreasing thereafter (56, 58). Infectious virus is detected in the nasal and oral secretions of infected animals between 2 and 5 dpi (56, 58), while no infectious virus was detected in feces (58). Shedding of viral RNA in feces was markedly lower and was characterized by intermittent detection of low amounts of viral RNA (56, 58). Consistent with active virus replication and shedding through respiratory and oral secretions, SARS-CoV-2 is efficiently transmitted between inoculated and contact WTD (5658). Transmission to contact fawns was observed on 3 dpi, a time point in which infectious virus shedding in nasal and oral secretions was abundant, but not on 6 or 9 dpi when no infectious virus was recovered from inoculated animals (58). Together these results demonstrate that WTD enable active SARS-CoV-2 replication in the respiratory tract with virus shedding and efficient transmission of the virus likely occurring through respiratory or oral secretions.

Pathology of SARS-CoV-2 in WTD

Infection with SARS-CoV-2 in WTD have not been associated with gross pathological lesions (5658). Histologically, white-tailed-deer infected with the ancestral B.1 lineage of SARS-CoV-2 presented with rhinitis characterized by submucosal lymphoplasmocytic infiltrates and frequent mucosal exudation of neutrophils in the nasal turbinate and moderate to abundant staining of viral RNA and NP is detected at 2 and 5 dpi. Of note, viral RNA and antigen distribution in nasal turbinate epithelial cells is consistent with detection of high levels of expression of the virus receptor ACE2 and the serine protease TMPRSS2 in these cells (58). In lungs, diffuse congestion of alveolar capillaries and multifocal hemorrhage in the submucosa of larger airways, and multifocal perivascular and interstitial lymphohistiocytic infiltrates are observed. Moderate to abundant viral RNA and antigen staining in the bronchial epithelial cells is observed at 2 dpi and is less evident at 5 dpi (58). In lymphoid organs (tonsil and lymph nodes), follicles exhibit moderate lymphoid depletion and lymphocytolysis. Tonsils also contain multifocal hemorrhages in crypt epithelium, crypts with variable numbers of neutrophils and cell debris, and congested vasculature filled with neutrophils. Numerous tonsillar follicles and overlying epithelium are positive for virus RNA and N antigen at 2 and 5 dpi (58). Notably, high ACE2 and TMPRSS2 expression have been detected in crypt epithelial cells and in germinal centers in the tonsil where active virus replication is detected (58). In addition, viral staining in the mandibular and/or retropharyngeal lymph nodes has been observed at 2 and 5 dpi, with the interfollicular and paracortical regions of these lymph nodes containing large foci of virus replication (58).

Immune responses to SARS-CoV-2 in WTD

SARS-CoV-2 infection in WTD result in the development of neutralizing antibodies to the virus as early as 7 dpi (5658). The geometric mean titers of neutralizing antibodies detected in WTD infected with the ancestral B.1 lineage of SARS-CoV-2 vary from 37 to 107, 85 to 214, and 85 to 256 on 7, 14, and 21 dpi, respectively (56). Antibodies against S RBD and NP are also detected upon infection and titers of antibodies against the nucleoprotein are lower and appear at later time points (14–18 dpi) (56, 57). Development and kinetics of neutralizing antibodies parallels with resolution of viral replication. No studies have been performed to date to assess T cell responses nor to define immunological cells and effector functions controlling infection in WTD.

Conclusions

SARS-CoV-2 presents a broad host tropism with a diverse array of susceptible domestic and wild animal species. Amongst those, domestic cats and WTD are exquisitely susceptible to infection and highly efficient in virus transmission. The infection dynamics of SARS-CoV-2, including virus replication kinetics and tissue tropism, transmission dynamics, cellular and humoral immune responses, and pathological changes in the respiratory tract in SARS-CoV-2 infected domestic cats resemble SARS-CoV-2 infections in humans. These initial studies elucidated basic aspects of SARS-CoV-2 pathogenesis and immune responses in domestic cats, however, functional details of the host innate, and cellular immune responses are still missing. Similarly, WTD are highly susceptible to SARS-CoV-2 infection, can transmit the virus and mount robust neutralizing antibody responses. Recent studies suggest that WTD may serve as a new wildlife reservoir for diverse ancestral SARS-CoV-2 lineages deserves special attention. Furthermore, the immune responses and viral factors leading to clearance or to possible virus persistence in WTD should be further studied as this may allow implementation of measures to effectively prevent or reduce infection rates in this animal population.

Funding:

This work was funded by the National Institute of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID) (award no. R01AI166791–01) and the United states Department of Agriculture (USDA) National Institute of Food and Agriculture (NIFA) (award no. 2023–70432–39463)

Abbreviations

SARS-CoV-2

severe acute respiratory syndrome coronavirus 2

COVID-19

coronavirus disease 2019

URT

upper respiratory tract

WTD

wild-tailed-deer

MERS-CoV

Middle East respiratory syndrome CoV

ACE2

angiotensin-converting enzyme 2

TMPRSS2

transmembrane protease, serine 2

RBD

receptor binding domain

RBM

receptor binding motif

FCS

furin cleavage site

ISH

in situ hybridization

dpi

days post-infection

TCID50

Tissue culture infectious dose 50.

References

  • 1.Cui J, Li F, and Shi Z-L. 2019. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol 17: 181–192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, and Tan W. 2020. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med 382: 727–733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Holmes EC, Goldstein SA, Rasmussen AL, Robertson DL, Crits-Christoph A, Wertheim JO, Anthony SJ, Barclay WS, Boni MF, Doherty PC, Farrar J, Geoghegan JL, Jiang X, Leibowitz JL, Neil SJD, Skern T, Weiss SR, Worobey M, Andersen KG, Garry RF, and Rambaut A. 2021. The origins of SARS-CoV-2: A critical review. Cell 184: 4848–4856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, and Cao B. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497–506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Xiao X, Newman C, Buesching CD, Macdonald DW, and Zhou Z-M. 2021. Animal sales from Wuhan wet markets immediately prior to the COVID-19 pandemic. Sci. Rep 11: 11898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Zhou H, Ji J, Chen X, Bi Y, Li J, Wang Q, Hu T, Song H, Zhao R, Chen Y, Cui M, Zhang Y, Hughes AC, Holmes EC, and Shi W. 2021. Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses. Cell 184: 4380–4391.e14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Lytras S, Hughes J, Martin D, Swanepoel P, de Klerk A, Lourens R, Kosakovsky Pond SL, Xia W, Jiang X, and Robertson DL. 2022. Exploring the natural origins of SARS-CoV-2 in the light of recombination. Genome Biol. Evol 14: evac018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Boni MF, Lemey P, Jiang X, Lam TT-Y, Perry BW, Castoe TA, Rambaut A, and Robertson DL. 2020. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. Nat. Microbiol 5: 1408–1417. [DOI] [PubMed] [Google Scholar]
  • 9.Zhou H, Chen X, Hu T, Li J, Song H, Liu Y, Wang P, Liu D, Yang J, Holmes EC, Hughes AC, Bi Y, and Shi W. 2020. A novel bat coronavirus closely related to SARS-CoV-2 contains natural insertions at the S1/S2 cleavage site of the spike protein. Curr. Biol 30: 2196–2203.e3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hu D, Zhu C, Ai L, He T, Wang Y, Ye F, Yang L, Ding C, Zhu X, Lv R, Zhu J, Hassan B, Feng Y, Tan W, and Wang C. 2018. Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese bats. Emerg. Microbes Infect 7: 1–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Worobey M, Levy JI, Malpica Serrano L, Crits-Christoph A, Pekar JE, Goldstein SA, Rasmussen AL, Kraemer MUG, Newman C, Koopmans MPG, Suchard MA, Wertheim JO, Lemey P, Robertson DL, Garry RF, Holmes EC, Rambaut A, and Andersen KG. 2022. The Huanan Seafood Wholesale Market in Wuhan was the early epicenter of the COVID-19 pandemic. Science 377: 951–959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Yang H, and Rao Z. 2021. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat. Rev. Microbiol 19: 685–700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Redondo N, Zaldívar-López S, Garrido JJ, and Montoya M. 2021. SARS-CoV-2 accessory proteins in viral pathogenesis: Knowns and unknowns. Front. Immunol 12: 708264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Zandi M, Shafaati M, Kalantar-Neyestanaki D, Pourghadamyari H, Fani M, Soltani S, Kaleji H, and Abbasi S. 2022. The role of SARS-CoV-2 accessory proteins in immune evasion. Biomed. Pharmacother 156: 113889. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, and Li F. 2020. Cell entry mechanisms of SARS-CoV-2. Proc. Natl. Acad. Sci. U. S. A 117: 11727–11734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Martin-Sancho L, Lewinski MK, Pache L, Stoneham CA, Yin X, Becker ME, Pratt D, Churas C, Rosenthal SB, Liu S, Weston S, De Jesus PD, O’Neill AM, Gounder AP, Nguyen C, Pu Y, Curry HM, Oom AL, Miorin L, Rodriguez-Frandsen A, Zheng F, Wu C, Xiong Y, Urbanowski M, Shaw ML, Chang MW, Benner C, Hope TJ, Frieman MB, García-Sastre A, Ideker T, Hultquist JF, Guatelli J, and Chanda SK. 2021. Functional landscape of SARS-CoV-2 cellular restriction. Mol. Cell 81: 2656–2668.e8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hossain Md. G., A. Javed, S. Akter, and S. Saha. 2021. SARS-CoV-2 host diversity: An update of natural infections and experimental evidence. J. Microbiol. Immunol. Infect 54: 175–181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.SARS-ANI VIS. 2023. A Global Open Access Dataset of Reported SARS-CoV-2 Events in Animals Available at: https://vis.csh.ac.at/sars-ani/#infections (Date accessed: 26 April 2023). [DOI] [PMC free article] [PubMed]
  • 19.Eckstrand CD, Baldwin TJ, Rood KA, Clayton MJ, Lott JK, Wolking RM, Bradway DS, and Baszler T. 2021. An outbreak of SARS-CoV-2 with high mortality in mink (Neovison vison) on multiple Utah farms. PLoS Pathog 17: e1009952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Jairak W, Chamsai E, Udom K, Charoenkul K, Chaiyawong S, Techakriengkrai N, Tangwangvivat R, Suwannakarn K, and Amonsin A. 2022. SARS-CoV-2 delta variant infection in domestic dogs and cats, Thailand. Sci. Rep 12: 8403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, Liu R, He X, Shuai L, Sun Z, Zhao Y, Liu P, Liang L, Cui P, Wang J, Zhang X, Guan Y, Tan W, Wu G, Chen H, and Bu Z. 2020. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2. Science 368: 1016–1020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Martins M, do Nascimento GM, Nooruzzaman M, Yuan F, Chen C, Caserta LC, Miller AD, Whittaker GR, Fang Y, and Diel DG. 2022. The Omicron variant BA.1.1 presents a lower pathogenicity than B.1 D614G and Delta variants in a feline model of SARS-CoV-2 infection. J Virol 96: e0096122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Schulz C, Wylezich C, Wernike K, Gründl M, Dangel A, Baechlein C, Hoffmann D, Röhrs S, Hepner S, Ackermann N, Sing A, Pink I, Länger B, Volk HA, Becher P, Sutter G, Neubauer-Juric A, von Köckritz-Blickwede M, Beer M, and Volz A. 2021. Prolonged SARS-CoV-2 RNA shedding from therapy cat after cluster outbreak in retirement home. Emerg. Infect. Dis 27: 1974–1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Carlos RSA, Mariano APM, Maciel BM, Gadelha SR, Melo Silva M, Belitardo EMMA, Rocha DJPG, Almeida JPP, Pacheco LGC, Aguiar ERGR, Fehlberg HF, and Albuquerque GR. 2021. First genome sequencing of SARS‐CoV‐2 recovered from an infected cat and its owner in Latin America. Transbound. Emerg. Dis 68: 3070–3074. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Pagani G, Lai A, Bergna A, Rizzo A, Stranieri A, Giordano A, Paltrinieri S, Lelli D, Decaro N, Rusconi S, Gismondo MR, Antinori S, Lauzi S, Galli M, and Zehender G. 2021. Human-to-cat SARS-CoV-2 transmission: Case report and full-genome sequencing from an infected pet and its owner in Northern Italy. Pathogens 10: 252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Neira V, Brito B, Agüero B, Berrios F, Valdés V, Gutierrez A, Ariyama N, Espinoza P, Retamal P, Holmes EC, Gonzalez-Reiche AS, Khan Z, van de Guchte A, Dutta J, Miorin L, Kehrer T, Galarce N, Almonacid LI, Levican J, van Bakel H, García-Sastre A, and Medina RA. 2021. A household case evidences shorter shedding of SARS-CoV-2 in naturally infected cats compared to their human owners. Emerg. Microbes Infect 10: 376–383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Klaus J, Meli M, Willi B, Nadeau S, Beisel C, Stadler T, Egberink H, Zhao S, Lutz H, Riond B, Rösinger N, Stalder H, Renzullo S, and Hofmann-Lehmann R. 2021. Detection and genome sequencing of SARS-CoV-2 in a domestic cat with respiratory signs in Switzerland. Viruses 13: 496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Klaus J, Palizzotto C, Zini E, Meli ML, Leo C, Egberink H, Zhao S, and Hofmann-Lehmann R. 2021. SARS-CoV-2 infection and antibody response in a symptomatic cat from Italy with intestinal B-cell lymphoma. Viruses 13: 527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Curukoglu A, Ergoren M, Ozgencil F, Sayiner S, Ince M, and Sanlidag T. 2021. First direct human‐to‐cat transmission of the SARS-CoV‐2 B.1.1.7 variant. Aust. Vet. J 99: 482–488. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Chaintoutis SC, Siarkou VI, Mylonakis ME, Kazakos GM, Skeva P, Bampali M, Dimitriou M, Dovrolis N, Polizopoulou ZS, Karakasiliotis I, and Dovas CI. 2022. Limited cross‐species transmission and absence of mutations associated with SARS‐CoV‐2 adaptation in cats: A case study of infection in a small household setting. Transbound. Emerg. Dis 69: 1606–1616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Hosie MJ, Epifano I, Herder V, Orton RJ, Stevenson A, Johnson N, MacDonald E, Dunbar D, McDonald M, Howie F, Tennant B, Herrity D, Da Silva Filipe A, Streicker DG, Willett BJ, Murcia PR, Jarrett RF, Robertson DL, and Weir W. 2021. Detection of SARS‐CoV‐2 in respiratory samples from cats in the UK associated with human‐to‐cat transmission. Vet. Rec 188: e247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Segalés J, Puig M, Rodon J, Avila-Nieto C, Carrillo J, Cantero G, Terrón MT, Cruz S, Parera M, Noguera-Julián M, Izquierdo-Useros N, Guallar V, Vidal E, Valencia A, Blanco I, Blanco J, Clotet B, and Vergara-Alert J. 2020. Detection of SARS-CoV-2 in a cat owned by a COVID-19−affected patient in Spain. Proc. Natl. Acad. Sci. U. S. A 117: 24790–24793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Zoccola R, Beltramo C, Magris G, Peletto S, Acutis P, Bozzetta E, Radovic S, Zappulla F, Porzio AM, Gennero MS, Dondo A, Pasqualini C, Griglio B, Ferrari A, Ru G, and Goria M. 2021. First detection of an Italian human-to-cat outbreak of SARS-CoV-2 Alpha variant – lineage B.1.1.7. One Health 13: 100295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Keller M, Hagag IT, Balzer J, Beyer K, Kersebohm JC, Sadeghi B, Wernike K, Höper D, Wylezich C, Beer M, and Groschup MH. 2021. Detection of SARS-CoV-2 variant B.1.1.7 in a cat in Germany. Res. Vet. Sci 140: 229–232. [DOI] [PubMed] [Google Scholar]
  • 35.Lenz OC, Marques AD, Kelly BJ, Rodino KG, Cole SD, Perera RAPM, Weiss SR, Bushman FD, and Lennon EM. 2022. SARS-CoV-2 Delta variant (AY.3) in the feces of a domestic cat. Viruses 14: 421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Sánchez-Morales L, Sánchez-Vizcaíno JM, Pérez-Sancho M, Domínguez L, and Barroso-Arévalo S. 2022. The Omicron (B.1.1.529) SARS-CoV-2 variant of concern also affects companion animals. Front. Vet. Sci 9: 940710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Gaudreault NN, Trujillo JD, Carossino M, Meekins DA, Morozov I, Madden DW, Indran SV, Bold D, Balaraman V, Kwon T, Artiaga BL, Cool K, García-Sastre A, Ma W, Wilson WC, Henningson J, Balasuriya UBR, and Richt JA. 2020. SARS-CoV-2 infection, disease and transmission in domestic cats. Emerg. Microbes Infect 9: 2322–2332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Bao L, Song Z, Xue J, Gao H, Liu J, Wang J, Guo Q, Zhao B, Qu Y, Qi F, Gong S, Liu M, Lv Q, Li D, Han Y, Zhao W, Deng S, Liu Y, Xiang Z, Yang B, Deng W, Yu H, Cong Z, Wei Q, Xu J, Gao GF, and Qin C. 2021. Susceptibility and attenuated transmissibility of SARS-CoV-2 in domestic cats. J. Infect. Dis 223: 1313–1321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Halfmann PJ, Hatta M, Chiba S, Maemura T, Fan S, Takeda M, Kinoshita N, Hattori S, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, and Kawaoka Y. 2020. Transmission of SARS-CoV-2 in domestic cats. N. Engl. J. Med 383: 592–594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Chiba S, Halfmann PJ, Hatta M, Maemura T, Fan S, Armbrust T, Swartley OM, Crawford LK, and Kawaoka Y. 2021. Protective immunity and persistent lung sequelae in domestic cats after SARS-CoV-2 infection. Emerg. Infect. Dis 27: 660–663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Bosco-Lauth AM, Hartwig AE, Porter SM, Gordy PW, Nehring M, Byas AD, VandeWoude S, Ragan IK, Maison RM, and Bowen RA. 2020. Experimental infection of domestic dogs and cats with SARS-CoV-2: Pathogenesis, transmission, and response to reexposure in cats. Proc. Natl. Acad. Sci. U. S. A 117: 26382–26388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Gaudreault NN, Carossino M, Morozov I, Trujillo JD, Meekins DA, Madden DW, Cool K, Artiaga BL, McDowell C, Bold D, Balaraman V, Kwon T, Ma W, Henningson J, Wilson DW, Wilson WC, Balasuriya UBR, García-Sastre A, and Richt JA. 2021. Experimental re-infected cats do not transmit SARS-CoV-2. Emerg. Microbes Infect 10: 638–650. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.APHIS USDA. 2021. Confirmed cases of SARS-CoV-2 in Animals in the United States Available at https://www.aphis.usda.gov/aphis/dashboards/tableau/sars-dashboard. Date accessed: 26 April 2023.
  • 44.American Veterinary Medical Association. 2020. SARS-CoV-2 in animals, including pets Available at: https://www.avma.org/resources-tools/one-health/covid-19/sars-cov-2-animals-including-pets. Date accessed: 26 April 2023.
  • 45.McAloose D, Laverack M, Wang L, Killian ML, Caserta LC, Yuan F, Mitchell PK, Queen K, Mauldin MR, Cronk BD, Bartlett SL, Sykes JM, Zec S, Stokol T, Ingerman K, Delaney MA, Fredrickson R, Ivančić M, Jenkins-Moore M, Mozingo K, Franzen K, Bergeson NH, Goodman L, Wang H, Fang Y, Olmstead C, McCann C, Thomas P, Goodrich E, Elvinger F, Smith DC, Tong S, Slavinski S, Calle PP, Terio K, Torchetti MK, and Diel DG. 2020. From people to Panthera: Natural SARS-CoV-2 infection in tigers and lions at the Bronx Zoo. mBio 11: e02220–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Grome HN, Meyer B, Read E, Buchanan M, Cushing A, Sawatzki K, Levinson KJ, Thomas LS, Perry Z, Uehara A, Tao Y, Queen K, Tong S, Ghai R, Fill M-M, Jones TF, Schaffner W, and Dunn J. 2022. SARS-CoV-2 outbreak among Malayan tigers and humans, Tennessee, USA, 2020. Emerg. Infect. Dis 28: 833–836. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Mitchell PK, Martins M, Reilly T, Caserta LC, Anderson RR, Cronk BD, Murphy J, Goodrich EL, and Diel DG. 2021. SARS-CoV-2 B.1.1.7 variant infection in Malayan tigers, Virginia, USA. Emerg. Infect. Dis 27: 3171–3173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Bartlett SL, Diel DG, Wang L, Zec S, Laverack M, Martins M, Caserta LC, Killian ML, Terio K, Olmstead C, Delaney MA, Stokol T, Ivančić M, Jenkins-Moore M, Ingerman K, Teegan T, McCann C, Thomas P, McAloose D, Sykes JM, and Calle PP. 2021. SARS-COV-2 infection and longitudinal fecal screening in Malayan tigers (Panthera tigris jacksoni), Amur tigers (Panthera tigris altaica), and African lions (Panthera leo krugeri) at the Bronx Zoo, New York, USA. J. Zoo Wildl. Med 51: 733–744. [DOI] [PubMed] [Google Scholar]
  • 49.Oreshkova N, Molenaar RJ, Vreman S, Harders F, Oude Munnink BB, Hakze-van der Honing RW, Gerhards N, Tolsma P, Bouwstra R, Sikkema RS, Tacken MG, de Rooij MM, Weesendorp E, Engelsma MY, Bruschke CJ, Smit LA, Koopmans M, van der Poel WH, and Stegeman A. 2020. SARS-CoV-2 infection in farmed minks, the Netherlands, April and May 2020. Euro. Surveill 25: 2001005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Larsen HD, Fonager J, Lomholt FK, Dalby T, Benedetti G, Kristensen B, Urth TR, Rasmussen M, Lassaunière R, Rasmussen TB, Strandbygaard B, Lohse L, Chaine M, Møller KL, Berthelsen A-SN, Nørgaard SK, Sönksen UW, Boklund AE, Hammer AS, Belsham GJ, Krause TG, Mortensen S, Bøtner A, Fomsgaard A, and Mølbak K. 2021. Preliminary report of an outbreak of SARS-CoV-2 in mink and mink farmers associated with community spread, Denmark, June to November 2020. Euro. Surveill 26: 2100009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Domańska-Blicharz K, Orłowska A, Smreczak M, Munnink BO, Trębas P, Socha W, Niemczuk K, Kawiak-Sadurska M, Opolska J, Lisowska A, Giza A, Bomba A, Iwan E, Koopmans M, and Rola J. 2022. SARS-CoV-2 monitoring on mink farms in Poland. J. Vet. Res 66: 449–458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Badiola JJ, Otero A, Sevilla E, Marín B, García Martínez M, Betancor M, Sola D, Pérez Lázaro S, Lozada J, Velez C, Chiner-Oms Á, Comas I, Cancino-Muñoz I, Monleón E, Monzón M, Acín C, Bolea R, and Moreno B. 2022. SARS-CoV-2 outbreak on a Spanish mink farm: Epidemiological, molecular, and pathological studies. Front. Vet. Sci 8: 805004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Shriner SA, Ellis JW, Root JJ, Roug A, Stopak SR, Wiscomb GW, Zierenberg JR, Ip HS, Torchetti MK, and DeLiberto TJ. 2021. SARS-CoV-2 exposure in escaped mink, Utah, USA. Emerg. Infect. Dis 27: 988–990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Hammer AS, Quaade ML, Rasmussen TB, Fonager J, Rasmussen M, Mundbjerg K, Lohse L, Strandbygaard B, Jørgensen CS, Alfaro-Núñez A, Rosenstierne MW, Boklund A, Halasa T, Fomsgaard A, Belsham GJ, and Bøtner A. 2021. SARS-CoV-2 transmission between mink (Neovison vison) and humans, Denmark. Emerg. Infect. Dis 27: 547–551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Rabalski L, Kosinski M, Mazur-Panasiuk N, Szewczyk B, Bienkowska-Szewczyk K, Kant R, Sironen T, Pyrc K, and Grzybek M. 2022. Zoonotic spill-over of SARS-CoV-2: mink-adapted virus in humans. Clin. Microbiol. Infect 28: 451.e1–451.e4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Palmer MV, Martins M, Falkenberg S, Buckley A, Caserta LC, Mitchell PK, Cassmann ED, Rollins A, Zylich NC, Renshaw RW, Guarino C, Wagner B, Lager K, and Diel DG. 2021. Susceptibility of white-tailed deer (Odocoileus virginianus) to SARS-CoV-2. J. Virol 95: e00083–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Cool K, Gaudreault NN, Morozov I, Trujillo JD, Meekins DA, McDowell C, Carossino M, Bold D, Mitzel D, Kwon T, Balaraman V, Madden DW, Artiaga BL, Pogranichniy RM, Roman-Sosa G, Henningson J, Wilson WC, Balasuriya UBR, García-Sastre A, and Richt JA. 2022. Infection and transmission of ancestral SARS-CoV-2 and its alpha variant in pregnant white-tailed deer. Emerg. Microbes Infect 11: 95–112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Martins M, Boggiatto PM, Buckley A, Cassmann ED, Falkenberg S, Caserta LC, Fernandes MHV, Kanipe C, Lager K, Palmer MV, and Diel DG. 2022. From Deer-to-Deer: SARS-CoV-2 is efficiently transmitted and presents broad tissue tropism and replication sites in white-tailed deer. PLoS Pathog 18: e1010197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Hale VL, Dennis PM, McBride DS, Nolting JM, Madden C, Huey D, Ehrlich M, Grieser J, Winston J, Lombardi D, Gibson S, Saif L, Killian ML, Lantz K, Tell RM, Torchetti M, Robbe-Austerman S, Nelson MI, Faith SA, and Bowman AS. 2022. SARS-CoV-2 infection in free-ranging white-tailed deer. Nature 602: 481–486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Marques AD, Sherrill-Mix S, Everett JK, Adhikari H, Reddy S, Ellis JC, Zeliff H, Greening SS, Cannuscio CC, Strelau KM, Collman RG, Kelly BJ, Rodino KG, Bushman FD, Gagne RB, and Anis E. 2022. Multiple introductions of SARS-CoV-2 Alpha and Delta variants into white-tailed deer in Pennsylvania. mBio 13: e0210122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Caserta LC, Martins M, Butt SL, Hollingshead NA, Covaleda LM, Ahmed S, Everts MRR, Schuler KL, and Diel DG. 2023. White-tailed deer (Odocoileus virginianus) may serve as a wildlife reservoir for nearly extinct SARS-CoV-2 variants of concern. Proc. Natl. Acad. Sci. U. S. A 120: e2215067120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Pickering B, Lung O, Maguire F, Kruczkiewicz P, Kotwa JD, Buchanan T, Gagnier M, Guthrie JL, Jardine CM, Marchand-Austin A, Massé A, McClinchey H, Nirmalarajah K, Aftanas P, Blais-Savoie J, Chee H-Y, Chien E, Yim W, Banete A, Griffin BD, Yip L, Goolia M, Suderman M, Pinette M, Smith G, Sullivan D, Rudar J, Vernygora O, Adey E, Nebroski M, Goyette G, Finzi A, Laroche G, Ariana A, Vahkal B, Côté M, McGeer AJ, Nituch L, Mubareka S, and Bowman J. 2022. Divergent SARS-CoV-2 variant emerges in white-tailed deer with deer-to-human transmission. Nat. Microbiol 7: 2011–2024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Tamil Selvan M, Gunasekara S, Xiao P, Griffin K, Cowan SR, Narayanan S, Ramachandran A, Hagen DE, Ritchey JW, Rudd JM, and Miller CA. 2022. SARS CoV-2 (Delta variant) infection kinetics and immunopathogenesis in domestic cats. Viruses 14: 1207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Rudd JM, Tamil Selvan M, Cowan S, Kao Y-F, Midkiff CC, Narayanan S, Ramachandran A, Ritchey JW, and Miller CA. 2021. Clinical and histopathologic features of a feline SARS-CoV-2 infection model are analogous to acute COVID-19 in humans. Viruses 13: 1550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Patania OM, Chiba S, Halfmann PJ, Hatta M, Maemura T, Bernard KA, Kawaoka Y, and Crawford LK. 2022. Pulmonary lesions induced by SARS-CoV-2 infection in domestic cats. Vet. Pathol 59: 696–706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.De Biasi S, Lo Tartaro D, Meschiari M, Gibellini L, Bellinazzi C, Borella R, Fidanza L, Mattioli M, Paolini A, Gozzi L, Jaacoub D, Faltoni M, Volpi S, Milić J, Sita M, Sarti M, Pucillo C, Girardis M, Guaraldi G, Mussini C, and Cossarizza A. 2020. Expansion of plasmablasts and loss of memory B cells in peripheral blood from COVID‐19 patients with pneumonia. Eur. J. Immunol 50: 1283–1294. [DOI] [PubMed] [Google Scholar]
  • 67.Damas J, Hughes GM, Keough KC, Painter CA, Persky NS, Corbo M, Hiller M, Koepfli K-P, Pfenning AR, Zhao H, Genereux DP, Swofford R, Pollard KS, Ryder OA, Nweeia MT, Lindblad-Toh K, Teeling EC, Karlsson EK, and Lewin HA. 2020. Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates. Proc. Natl. Acad. Sci. U. S. A 117: 22311–22322. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES